All canine diagnoses

Your dog was diagnosed with Primary Pulmonary Carcinoma. ~1% of all canine tumours. Often incidental finding on thoracic imaging. Adenocarcinoma is the most common histotype. Solitary masses have better prognosis than multiple nodules. Compare 3 treatment options for dogs including Lung Lobectomy, Metronomic Chemotherapy (Inoperable/Advanced), Palliation / Supportive Care — with survival times, costs, and what to expect during treatment.

🐕

Primary Pulmonary Carcinoma

Based on tumour number, size, LN status

BreedsNo strong breed predispositionPossibly BoxerDoberman Pinscher
canine

Epithelial

About This Cancer

Primary lung cancer in dogs — as distinct from cancer that has spread (metastasised) to the lungs from elsewhere — arises from the cells lining the airways or air sacs. Adenocarcinoma is the most common type. The tumour typically presents as a solitary mass within one lung lobe, often discovered incidentally on chest X-rays taken for other reasons. When symptoms are present, they may include coughing, exercise intolerance, or laboured breathing. The outlook depends largely on whether the tumour is a single mass (better prognosis) or multiple nodules (worse), whether lymph nodes are involved, and whether the tumour can be completely removed by surgery. Dogs with a single lung mass and no lymph node involvement have the best outcome following lung lobectomy, with some living two or more years. Primary lung cancer represents only about 1% of all canine tumours and is not associated with strong breed predispositions.

Modified staging for canine primary lung tumours

Based on tumour number, size, lymph node involvement

Stage T1Single small tumour (<5 cm), no LN involvement
Stage T2Single tumour >5 cm or multiple tumours, no LN involvement
Stage T3Any tumour with lymph node involvement or direct invasion of adjacent structures
Stage M1Distant metastasis
Prognostic Factors(3)
Lymph node statusTracheobronchial LN metastasis significantly shortens survival. LN- dogs: MST >12 months post-lobectomy. LN+ dogs: MST ~2 months.(McNiel et al., 1997)
Tumour size and numberSolitary tumour: best prognosis. Multiple nodules: worse but may still benefit from surgery.
Histological gradeWell-differentiated tumours have better prognosis. Anaplastic tumours carry worst prognosis.
Minimum Workup(6 steps)
1Thoracic CT (superior to radiographs for characterisation, LN assessment)
2Thoracic radiographs (3-view) if CT not available
3Abdominal ultrasound (metastasis screening, primary tumour rule-out)
4CT-guided or bronchoscopic biopsy if diagnosis uncertain
5Complete blood count and biochemistry
6Urinalysis (rule out digit metastasis — lung-digit syndrome consideration)

Median Survival Time Comparison

How long the average patient survives with each treatment

Bar opacity reflects evidence strength
Lung Lobectomy
~12 mo (8–24)
Metronomic Chemotherapy (Inoperable/Advanced)
~5 mo (3–8)
Palliation / Supportive Care
~3 mo (1–6)
Reading this page: MST (Median Survival Time) is how long the average patient survives with a given treatment. ORR (Overall Response Rate) is the percentage of patients whose tumour shrank or disappeared. CR = Complete Response (tumour gone); PR = Partial Response (tumour shrank). Hover over any abbreviation for a quick explanation.
Strength of Evidence

Each treatment is rated by how much published research supports its use. Solid bars indicate stronger evidence; dashed bars mean less certainty.

StrongLarge published studies with strong agreement among veterinary oncologists.
ModerateWidely used in clinical practice, but supported by smaller or retrospective studies.
IndirectEvidence comes from a different tumour type or species and has been applied here.
LimitedVery little published data is available for this specific treatment.

Please note: All treatment data is sourced from published peer-reviewed literature. Survival times and cost figures are approximate guides. Your pet's individual factors — including tumour grade, stage, and overall health — will influence outcomes and should guide all treatment decisions. The strength-of-evidence rating reflects how much research exists, not how strongly a treatment is recommended. This tool is designed to help you have informed conversations with your veterinary oncologist, not to replace them. Costs shown are US referral centre estimates and may vary significantly by region.